FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

By Sean Whooley | March 19, 2021

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment.

Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Neurological Disease
Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].